featured
Long-Term Outcomes by Bone Marrow B-Cell Depletion in Patients With Waldenstrőm Macroglobulinaemia Receiving Bortezomib With Cyclophosphamide and Rituximab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia
Leukemia 2024 Feb 26;[EPub Ahead of Print], R de Tute, N Counsell, L Clifton-Hadley, S D'Sa, G Pratt, G Campbell, L Campbell, R Sadler, W Townsend, B Popova, P Smith, O Schofield, R Owen, R AuerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.